AGL 37.80 Increased By ▲ 0.30 (0.8%)
AIRLINK 218.50 Decreased By ▼ -4.39 (-1.97%)
BOP 10.93 Increased By ▲ 0.11 (1.02%)
CNERGY 7.57 Increased By ▲ 0.01 (0.13%)
DCL 9.16 Decreased By ▼ -0.26 (-2.76%)
DFML 40.35 Decreased By ▼ -0.61 (-1.49%)
DGKC 102.11 Decreased By ▼ -4.65 (-4.36%)
FCCL 34.95 Decreased By ▼ -2.12 (-5.72%)
FFL 19.50 Increased By ▲ 0.26 (1.35%)
HASCOL 12.70 Decreased By ▼ -0.48 (-3.64%)
HUBC 131.00 Decreased By ▼ -1.64 (-1.24%)
HUMNL 14.59 Decreased By ▼ -0.14 (-0.95%)
KEL 5.19 Decreased By ▼ -0.21 (-3.89%)
KOSM 7.35 Decreased By ▼ -0.13 (-1.74%)
MLCF 45.80 Decreased By ▼ -2.38 (-4.94%)
NBP 66.04 Decreased By ▼ -0.25 (-0.38%)
OGDC 223.50 Increased By ▲ 0.24 (0.11%)
PAEL 44.30 Increased By ▲ 0.80 (1.84%)
PIBTL 9.01 Decreased By ▼ -0.06 (-0.66%)
PPL 194.00 Decreased By ▼ -4.24 (-2.14%)
PRL 43.50 Increased By ▲ 1.26 (2.98%)
PTC 26.62 Decreased By ▼ -0.77 (-2.81%)
SEARL 107.00 Decreased By ▼ -3.08 (-2.8%)
TELE 10.14 Decreased By ▼ -0.38 (-3.61%)
TOMCL 35.95 Decreased By ▼ -0.67 (-1.83%)
TPLP 14.58 Decreased By ▼ -0.37 (-2.47%)
TREET 25.98 Decreased By ▼ -0.55 (-2.07%)
TRG 67.40 Decreased By ▼ -1.45 (-2.11%)
UNITY 33.59 Decreased By ▼ -0.60 (-1.75%)
WTL 1.73 Decreased By ▼ -0.06 (-3.35%)
BR100 12,397 Increased By 33.3 (0.27%)
BR30 37,347 Decreased By -871.2 (-2.28%)
KSE100 117,587 Increased By 467.3 (0.4%)
KSE30 37,065 Increased By 128 (0.35%)

BEIJING: A China-developed coronavirus vaccine could be ready for the public as early as November, a Chinese official has told state television, as the global race to clear the final round of trials heats up.

Chinese manufacturers have been bullish about development, with companies Sinovac Biotech and Sinopharm even putting their vaccine candidates on display at a trade fair in Beijing this month.

Representatives of the firms told AFP that they hope their vaccines will be approved after phase 3 trials as early as year-end. And on late Monday, the chief biosafety expert at the Chinese Centre for Disease Control told state broadcaster CCTV that a vaccine would be available to the general public "around November or December."

Wu Guizhen did not specify which vaccine she was referring to, but said "based on the phase 3 clinical results, the current progress is very smooth."

Wu added that she had taken a vaccine in April and has felt good over the past few months, although she did not specify which candidate she had taken. There are currently nine vaccine candidates in late-stage human trials, although some have hit recent obstacles - pharma giant AstraZeneca and Oxford University momentarily paused clinical trials last week after a volunteer developed an unexplained illness.

Some of China's vaccine candidates have already been offered to essential workers under an emergency use programme. A Sinovac spokesman told AFP this month that "tens of thousands" of people had voluntarily taken its vaccine, including 90 percent of its employees and their families - between 2,000 and 3,000 people. In June, China's military approved a vaccine for use within its ranks developed by its research unit and a biotech firm.

Comments

Comments are closed.